August Nielsen, Simone Diedrichsen Marstrand, Djordje Marina, Michael Andersson, Lars Thorbjørn Jensen, Kristian Buch-Larsen, Peter Schwarz
{"title":"Assessing Chemotherapy-Induced Peripheral Neuropathy in Postmenopausal Breast Cancer Patients Using Vibration Perception Threshold.","authors":"August Nielsen, Simone Diedrichsen Marstrand, Djordje Marina, Michael Andersson, Lars Thorbjørn Jensen, Kristian Buch-Larsen, Peter Schwarz","doi":"10.1080/07357907.2025.2510996","DOIUrl":null,"url":null,"abstract":"<p><p>This study investigated the 3-year development of chemotherapy-induced peripheral neuropathy (CIPN) in post-menopausal women diagnosed with early breast cancer (EBC) using vibration perception threshold (VPT) measurements and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (CIPN18). 90 patients (aged 50-70) and 30 healthy subjects were included in the study. VPT measurements and CIPN18 questionnaires were performed post-chemotherapy (median 72 (IQR: 53-93) days post chemotherapy) as well as at the 12 and 36-month follow-up. Post-chemotherapy data showed impaired VPT measurements when comparing our study population to controls, but spontaneous improvement occurred, and by the 36-month follow-up, VPT measurements normalized when compared to controls. Mean CIPN18 scores improved, though the improvement was not statistically significant. Spearman's rho between VPT measurements and CIPN18 questionnaires showed weak to moderate correlations during follow-up. However, further analyses using a Generalized Additive Model confirmed the absence of a significant correlation between VPT measurements and CIPN18 questionnaires. Our data highlight limitations in the relationship between VPT measurements and CIPN. However, VPT measurements may have potential as an objective supplement to general assessment of patients.</p>","PeriodicalId":9463,"journal":{"name":"Cancer Investigation","volume":" ","pages":"1-11"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/07357907.2025.2510996","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
This study investigated the 3-year development of chemotherapy-induced peripheral neuropathy (CIPN) in post-menopausal women diagnosed with early breast cancer (EBC) using vibration perception threshold (VPT) measurements and the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (CIPN18). 90 patients (aged 50-70) and 30 healthy subjects were included in the study. VPT measurements and CIPN18 questionnaires were performed post-chemotherapy (median 72 (IQR: 53-93) days post chemotherapy) as well as at the 12 and 36-month follow-up. Post-chemotherapy data showed impaired VPT measurements when comparing our study population to controls, but spontaneous improvement occurred, and by the 36-month follow-up, VPT measurements normalized when compared to controls. Mean CIPN18 scores improved, though the improvement was not statistically significant. Spearman's rho between VPT measurements and CIPN18 questionnaires showed weak to moderate correlations during follow-up. However, further analyses using a Generalized Additive Model confirmed the absence of a significant correlation between VPT measurements and CIPN18 questionnaires. Our data highlight limitations in the relationship between VPT measurements and CIPN. However, VPT measurements may have potential as an objective supplement to general assessment of patients.
期刊介绍:
Cancer Investigation is one of the most highly regarded and recognized journals in the field of basic and clinical oncology. It is designed to give physicians a comprehensive resource on the current state of progress in the cancer field as well as a broad background of reliable information necessary for effective decision making. In addition to presenting original papers of fundamental significance, it also publishes reviews, essays, specialized presentations of controversies, considerations of new technologies and their applications to specific laboratory problems, discussions of public issues, miniseries on major topics, new and experimental drugs and therapies, and an innovative letters to the editor section. One of the unique features of the journal is its departmentalized editorial sections reporting on more than 30 subject categories covering the broad spectrum of specialized areas that together comprise the field of oncology. Edited by leading physicians and research scientists, these sections make Cancer Investigation the prime resource for clinicians seeking to make sense of the sometimes-overwhelming amount of information available throughout the field. In addition to its peer-reviewed clinical research, the journal also features translational studies that bridge the gap between the laboratory and the clinic.